Chinese medical-aesthetics company making injectable hyaluronic-acid dermal fillers (TradingView's specialty-chemicals label understates its health-care nature).
Chinese medical-aesthetics company making injectable hyaluronic-acid dermal fillers (TradingView's specialty-chemicals label understates its health-care nature).
Sells injectable fillers to clinics and hospitals, with each product needing approval from China's drug regulator as a medical device, so its approved range, not factory output, limits sales. Clinics, not patients, are the direct buyers, so doctors' preference matters.
In one line: A Chinese Allergan Aesthetics (dermal fillers)/Galderma.
Moat: narrow (regulatory licence, brand, IP / patents). Regulatory approval for injectable fillers is slow to obtain; IMEIK holds one of the broadest approved filler portfolios in China.
Headquarters: Beijing, China · Employees: 1,458
Size IMEIK Technology Development (300896.SZ) is a China Materials company (Chemicals: Specialty) with a market value of $3.66B, the 657th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥85.27 on 18 Nov 2026.
Performance Over six months the shares fell 24.9%, against -25.7% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue fell 7.3% over the last twelve months (peer median +10.9%); the operating margin is 44.6% (peer median 12.0%).
Valuation It trades at 22.4× forward earnings against a peer median of 14.9× (8th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.7 points above its cost of capital (11.1% WACC).
Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.33B | CN¥2.42B | CN¥3.01B | CN¥2.86B | CN¥1.93B |
| Revenue growth | — | -20% | +5% | +48% | — |
| Gross profit | CN¥2.16B | CN¥2.19B | CN¥2.80B | CN¥2.67B | CN¥1.81B |
| EBITDA | n/a | CN¥1.39B | CN¥2.20B | CN¥2.11B | CN¥1.40B |
| Net income | CN¥989M | CN¥1.29B | CN¥1.96B | CN¥1.86B | CN¥1.26B |
| Free cash flow | CN¥888M | CN¥1.22B | CN¥1.74B | CN¥1.92B | CN¥1.06B |
| Capital expenditure | CN¥191M | CN¥171M | CN¥239M | CN¥63.7M | CN¥156M |
| Total debt | CN¥31.9M | CN¥32.1M | CN¥45.0M | CN¥52.5M | CN¥59.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| IMEIK Technology Development 300896.SZ | $3.66B | -25% | -7% | 45% | 22.4× | 17.5% |
| Bloomage Biotechnology 688363.SS | $2.27B | -21% | -22% | 5% | 52.0× | 19.0% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 18.1× | -0.1% |
| Galderma GALD.SW | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300896.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.8% | -4.3% | 4th lowest of 21 |
| 6-month return | -24.9% | -25.7% | 10th highest of 21 |
| Distance from 52-week high | -47.6% | -41.9% | 5th lowest of 21 |
| Revenue growth (TTM) | -7.3% | +10.9% | lowest of 21 |
| Operating margin | 44.6% | 12.0% | highest of 21 |
| Forward P/E | 22.4× | 14.9× | 8th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 17.5% | 3.6% | 3rd most demanding of 17 |
| Growth delivered (Del g) | +28.0% | +8.4% | 2nd highest of 17 |
| Hurdle (Req g minus delivered) | -10.5 pp | -4.4 pp | 7th least demanding of 17 |
| ROIC minus cost of capital | +3.7 pp | +1.8 pp | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| IMEIK Technology Development 300896.SZ | China | $3.66B | -25% | -7% | 45% | 22.4× | 17.5% | +28.0% |
| Do-Fluoride New Materials 002407.SZ | China | $3.62B | -42% | +69% | 7% | 33.9× | 17.3% | +17.5% |
| Hangzhou Oxygen Plant 002430.SZ | China | $3.70B | -16% | +16% | 11% | 19.8× | 2.2% | +8.5% |
| Bluestar Adisseo 600299.SS | China | $3.70B | -34% | +15% | 13% | 11.3× | -9.4% | +7.7% |
| NOF 4403.T | Japan | $3.60B | -10% | +22% | 17% | 13.6× | -7.4% | +8.4% |
| Pangang Group Vanadium & Titanium Resources 000629.SZ | China | $3.60B | -26% | +6% | 4% | 57.3× | 26.1% | -3.4% |
| Mitsubishi Gas Chemical 4182.T | Japan | $3.76B | -32% | +9% | 9% | 10.2× | n/a | n/a |
| Cathay Biotech 688065.SS | China | $3.77B | -23% | +9% | 18% | 34.3× | n/a | n/a |
| Cabot CBT | United States | $3.80B | -5% | +1% | 14% | 11.3× | -2.3% | +1.9% |
| Novoray 688300.SS | China | $3.40B | -39% | +23% | 26% | 49.8× | 45.5% | +22.6% |
| Inner Mongolia Berun Chemical 000683.SZ | China | $3.28B | -27% | +11% | 13% | 13.8× | n/a | n/a |
| Ningbo Shanshan 600884.SS | China | $3.27B | -35% | +30% | 9% | 12.2× | 2.8% | +21.3% |
| GEM 002340.SZ | China | $4.12B | -35% | +2% | 7% | 14.6× | 3.5% | +24.4% |
| Zhejiang Sanmei Chemical Industry 603379.SS | China | $4.20B | -27% | +24% | 41% | 12.2× | 3.8% | +16.5% |
| Hawkins HWKN | United States | $3.19B | -1% | +9% | 11% | 34.4× | 15.9% | +12.7% |
| Clariant CLN.SW | Switzerland | $4.20B | +35% | -7% | 10% | 16.3× | -3.3% | +0.3% |
| Guangxi Huaxi Nonferrous Metal 600301.SS | China | $4.27B | -25% | +24% | 32% | 22.6× | 9.1% | +44.9% |
| Hexpol HPOL-B.ST | Sweden | $3.10B | +19% | -1% | 14% | 15.2× | 2.9% | +7.6% |
| Air Water 4088.T | Japan | $4.34B | +34% | +11% | 3% | 11.8× | 9.4% | +6.8% |
| Far Eastern New Century 1402.TW | Taiwan | $4.39B | +2% | +5% | 7% | 11.5× | 4.7% | +4.2% |
| Guangzhou Guanggang Gases and Energy 688548.SS | China | $3.02B | -26% | +21% | 20% | 55.4× | n/a | n/a |